Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmacyclics, Inc.
Market Intel: Opportunities for Medtech In Mental Health (Part 1) – Transcranial Magnetic Stimulation
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In this first part of a two-part series focusing on mental health tech, Medtech Insight focuses on transcranial magnetic stimulation systems used to treat severe anxiety and depression, among other indications. Part two will focus on the skyrocketing use of telehealth, apps and light therapy.
Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
While US regulators have ramped up the number of authorizations they’ve granted to companies on an emergency basis in response to the COVID-19 crisis, they really kicked things into high gear in just the past few days. On 10 April the agency issued a record number of EUAs in response to the pandemic.